CD4 and Hepatitis: Two of 17 (12%) CMV IgG+ CD4+ TEM≥16% patients (green box) did not develop hepatitis: one of these received four rounds of αPD-1/αCTLA-4 therapy and registered no complications; however, the other received only 1 round of αPD-1/αCTLA-4 before treatment with prednisolone from weeks 2 to 7 for colitis.